Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc. engages in developing and producing Stabilized Hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. Its products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. The company was founded by Hojabr Alimi and Linda Alimi in April 1999 and is headquartered in Boulder, CO.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sonoma Pharmaceuticals, Inc. engages in the development and production of hypochlorous acid (HOCl) products for wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. The company was founded by Hojabr Alimi and Linda Alimi in April 1999 and is headquartered in Boulder, CO.

BOULDER, CO / ACCESSWIRE / October 6, 2022 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, and dermatological conditions, announced that it will be exhibiting at the CPHI Conference in Frankfurt, Germany on November 1-3, 2022. Sonoma Pharmaceuticals is seeking to expand its presence in the European Union by adding new partners and distributors for its dermatology products, including treatments for scar management, atopic dermatitis and acne.

Sonoma Pharmaceuticals to Exhibit at Upcoming CPHI Conference in Frankfurt, Germany

Revenue increase of 73% from Q4 22 and 8% from Q1 22 Reduction of net loss by $0.2 million or 19% versus Q1 22 Reduction of EBITDAS loss by $0.2 million or 23% versus Q1 22 Reduction in net loss per share of 44% versus Q1 22 BOULDER, CO / ACCESSWIRE / August 11, 2022 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA),a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, and dermatological conditions, today announced financial results for its first fiscal quarter ended June 30, 2022. "Our first quarter results reflect our continued prioritization of growth and profitability," said Amy Trombly, CEO of Sonoma.

Sonoma Pharmaceuticals Reports First Quarter 2023 Financial Results

WOODSTOCK, GA / ACCESSWIRE / August 2, 2022 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, and dermatological conditions, today announced that it has launched a MicrocynVS® line of products exclusively for veterinarians. Veterinarian-strength MicrocynVS is formulated for the management of wound, skin, ear and eye afflictions in all animal species.

Sonoma Pharmaceuticals Launches MicrocynVS(R) Line of Products Exclusively for Veterinarian Use and Announces Partnership with DV Medical Supply

Revenues increased 7% in Q4 2022 compared to Q4 2021 Net loss per share improved quarter over quarter and year over year Strong balance sheet with $7.4 million of cash WOODSTOCK, GA / ACCESSWIRE / July 13, 2022 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA),a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications including wound, eye, oral and nasal care and dermatological conditions, today announced financial results for fiscal year 2022 and the fourth quarter ended March 31, 2022. "Our fourth quarter continues to reflect the restructuring and transition from Sonoma's last two years," commented Amy Trombly, CEO of Sonoma.

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2022 Financial Results

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions and disinfectant use, and its partner, the MicroSafe Group DMCC, are pleased to announce that Nanocyn® hospital grade disinfectant has been added to the list of COVID-19 disinfectants m

Sonoma Pharmaceuticals and MicroSafe Group DMCC Announce that U.S. EPA has Added Nanocyn® Hospital-Grade Disinfectant to List N for Use Against COVID-19

Sonoma Pharmaceuticals (SNOA) stock is getting a boost on Tuesday after the company revealed positive disinfectant news from the EPA. The post Why Is Sonoma Pharmaceuticals (SNOA) Stock Up 30% Today?

Why Is Sonoma Pharmaceuticals (SNOA) Stock Up 30% Today?

Graphite Bio

Harbor Custom Development, Inc.

What to know about buying penny stocks on May 3rd The post Best Penny Stocks to Buy Today? 3 to Watch on May 3rd appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy Today? 3 to Watch on May 3rd

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions and disinfectant use, and its partner, the MicroSafe Group DMCC, received EPA approval for Nanocyn® as a hospital-grade disinfectant in the United States. Nanocyn®, which is manufacture

Sonoma Pharmaceuticals and MicroSafe Group DMCC Announce EPA Approval for Nanocyn® Hospital-Grade Disinfectant in the U.S.

Adagio Therapeutics

Direct Digital Holdings

Geron

NanoVibronix

Vyant Bio

Penny stocks are a hot subject today with several of the top companies in the market seeing major gains on Wednesday and we know why! The post Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today?

Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today?

Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) has launched Microdox, an urinary tract infection catheter and bladder rinse in New Zealand, Australia, and South Africa. Microdox is a super-oxidized solution based on Sonoma's patented Microcyn Technology intended to treat and prevent.

Sonoma Pharma Launches New Urinary Tract Infection Product In New Zealand, Australia, South Africa

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, and dermatological conditions, today announced that it has launched Microdox®, an urinary tract infection catheter and bladder rinse in New Zealand, Australia and South Africa. Microdox® is a super-oxidized solu

Sonoma Pharmaceuticals Launches New Urinary Tract Infection Product Through Distributors in New Zealand, Australia and South Africa

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care and dermatological conditions today announced financial results for its third fiscal quarter and nine months ended December 31, 2021. “We continue to reshape Sonoma into a healthier company by divesting unprofitable product lines while

Sonoma Pharmaceuticals Reports Third Quarter FY 2022 Financial Results

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care and dermatological conditions, today announced that it will be featured as a presenting company at the H.C. Wainwright BioConnect Conference. The conference is being held on January 10-13, 2022 virtually. Amy Trombly, CEO and Jerry Dvon

Sonoma Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference January 10-13, 2022

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care and dermatological conditions today announced financial results for its second fiscal quarter and six months ended September 30, 2021. “This quarter we focused on our new product launches as well as strengthening our results of operatio

Sonoma Pharmaceuticals Reports Second Quarter FY 2022 Financial Results

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions and disinfectant use, and its long-time partner, Dyamed Biotech Pte Ltd., announce a renewed and expanded long-term partnership for Singapore, Malaysia, Indonesia and Thailand for multiple indications using So

Sonoma Pharmaceuticals and Dyamed Biotech Announce Expanded Long-Term Partnership for New Territories and Products in Southeast Asia

The stock price of Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) increased by over 20% pre-market today. This is why it happened.

SNOA Stock: Why The Price Increased Substantially Today

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions and disinfectant use, and its partner, the MicroSafe Group, announce that the Australian Therapeutic Goods Administration (TGA) has approved extended claims for Nanocyn® Disinfectant and Sanitizer, which is ma

Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn® Disinfectant & Sanitizer Has Been Approved by the Australia TGA with a 15 Second SARS-CoV-2 (COVID-19) Kill Time

Camber Energy

Farmmi

Houston American Energy

ReWalk Robotics

Alkaline Water Company Inc (The)

Penny stocks can be risky investments. These seven popular penny stocks seem like particularly bad bets no matter how you look at it.

7 Popular Penny Stocks That You Shouldn't Touch With a 10-Foot Pole

Today, investors in Sonoma Pharmaceuticals and SNOA stock are seeing impressive gains as the company launches its products on Amazon. The post Why SNOA Stock Is Getting a Bezos-Sized Boost Today appeared first on InvestorPlace.

Why SNOA Stock Is Getting a Bezos-Sized Boost Today

Shares of Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) jumped 70% in premarket trading on Tuesday as the company launched its first-ever over-the-counter products on Amazon. Sonoma debuts in the OTC market According to the press release, Sonoma Pharmaceuticals limited its offerings to “prescription or office dispense products” available only from physicians for over two decades.

Here's why Sonoma Pharmaceuticals is up 70% on Tuesday morning

The stock price of Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) increased by over 65% pre-market today. This is why it happened.

SNOA Stock: Why It Substantially Increased Today

Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) has announced the OTC consumer launch of Regenacyn Advanced Scar Gel and Ocucyn Eyelid & Eyelash Cleanser on Amazon.com and MucoClyns on Amazon sites in Europe.  All three products are based on Sonoma's Microcyn technology and are immediately available for customer orders.

Why Are Sonoma Pharma Shares Rallying Today?

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, and dermatological conditions, today announced the over-the-counter (“OTC”) consumer launch of Regenacyn® Advanced Scar Gel and Ocucyn® Eyelid & Eyelash Cleanser on Amazon.com, and MucoClyns™ on Amazon sites in Europe. All three pr

Sonoma Pharmaceuticals Launches Its First Over-the-Counter Products in the U.S. on Amazon and a New Consumer-Focused Product on Amazon in Europe

Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) is trading significantly lower Friday amid possible profit taking after the stock surged Thursday following the company's launch of two new dental products. Sonoma Pharmaceuticals launched OroGenix Oral Hygiene Rinse, which was developed with Gabriel Science and is the company's second dental product in the U.S. OroGenix Oral Hygiene Rinse uses Sonoma's patented Microcyn technology to cleanse teeth, gums, and mouth.

Why Sonoma Pharmaceuticals Shares Are Trading Lower Today

Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) is surging higher Thursday after the company announced it launched two new dental products.  Sonoma Pharmaceuticals launched OroGenix Oral Hygiene Rinse, which was developed with Gabriel Science and is the company's second dental product in the U.S. OroGenix Oral Hygiene Rinse uses Sonoma's patented Microcyn technology to cleanse teeth, gums, and mouth.

News for Sonoma Pharmaceuticals Stock (SNOA)